Skip to main content

Table 1 Post-infarction angiotensin converting enzyme-inhibitor trials

From: How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial

  Unselected post-infarction patients Post-infarction patients with left ventricular dysfunction
Trial CONSENSUS II GISSI-3 ISIS-4 SAVE AIRE SMILE TRACE
[Reference no] [16] [8] [7] [10] [12] [9] [11]
Drug Enalapril Lisinopril Captopril Captopril Ramipril Zofenopril Trandolapril
Number of patients 6090 19,394 58,050 2231 2006 1556 1749
Target dose 20 mg × 1 10 mg × 1 50 mg × 2 50 mg × 3 5 mg × 2 30 mg × 2 4 mg × 1
Inclusion criteria AMI AMI AMI LVEF < 40% Signs or Anterior wall Low wall
  consecutively consecutively consecutively   symptoms of AMI without motion index
      heart failure thrombolytics score
Follow-up time 1.5-6 months 6 weeks 5 weeks 24-60 months 6-30 months 6 weeks 24-50 months
  (trial stopped)       
Mortality reduction P: 10.2% P: 7.1% P: 7.7% P: 25% P: 23% P: 10.6% P : 42.3%
  T: 11.0% T: 6.3% T: 7.2% T: 20% T: 17% T: 7.1% T: 34.7%
Risk reduction -10 % 12% 7% 19% 27% 25% 22%
(95% CI) (-29 to 7%) (1% to 21%) (1% to 13%) (3% to 32%) (11% to 40%) (-11% to 60% (9% to 33%)
Level of significance P = 0.26 P = 0.03 P = 0.02 P = 0.019 P = 0.002 P = 0.19 P = 0.001
  1. AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; P, placebo; T, treatment; CI, confidence interval.